Earnings ·
TransMedics reports Q3 revenue of $203M and raises full-year 2026 guidance to $764-$774M
TMDXTransMedics Group, Inc.
TransMedics Group reported third-quarter 2026 total revenue of $203.0 million, a 41% increase from the prior year period, driven by higher organ volume and logistics services. The company posted net income of $17.1 million, or $0.46 per diluted share, and raised its full-year 2026 revenue guidance to between $764 million and $774 million. TransMedics operates in the medical technology industry, developing portable extracorporeal warm perfusion systems for organ transplantation.